Industry
Biotechnology
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 12:33 pm
Portfolio Pulse from Vandana Singh
August 13, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 12:30 pm
Portfolio Pulse from Vandana Singh
August 07, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 1:14 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 12:33 pm
Portfolio Pulse from Avi Kapoor
July 23, 2024 | 6:32 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.